Dose‐finding results in an adaptive, seamless, randomized trial of once‐weekly dulaglutide combined with metformin in type 2 diabetes patients (<scp>AWARD</scp>‐5)Zachary Skrivanek, Donald A. Berry, Scott Berry et al.|Diabetes Obesity and Metabolism|2014Cited by 72
An Adaptive, Dose-Finding, Seamless Phase 2/3 Study of a Long-Acting Glucagon-like Peptide-1 Analog (Dulaglutide): Trial Design and Baseline CharacteristicsMary Jane Geiger, James H. Anderson, Zachary Skrivanek et al.|Journal of Diabetes Science and Technology|2012Cited by 40
Application of Adaptive Design Methodology in Development of a Long-Acting Glucagon-like Peptide-1 Analog (Dulaglutide): Statistical Design and SimulationsZachary Skrivanek, Brenda Gaydos, Jenny Y. Chien et al.|Journal of Diabetes Science and Technology|2012Cited by 33
A Clinical Utility Index for Selecting an Optimal Insulin Dosing Algorithm for LY2605541 in Patients with Type 2 Diabetes Pretreated with Basal InsulinDavid H. Manner, Scott J. Jacober, Scott Berry et al.|Diabetes Technology & Therapeutics|2014Cited by 1